All In Biotech

Drug Trial Radar · NCT06046274

GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

A Phase 2 Exploratory, Multicenter, Open-Label Trial to Determine the Safety and Preliminary Clinical Activity of GEN1046 in Combination With Anticancer Agents in Subjects With Advanced Endometrial Cancer

Last checked: Nov 19, 2026Latest source record: Apr 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Oct 1, 2023

Primary completion

Apr 1, 2028

Study completion Jun 1, 2028

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
Collaborators
BioNTech SE
First posted
Sep 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn about the bispecific antibody, acasunlimab (also known as GEN1046) in combination with the cancer drug pembrolizumab for treatment of participants with incurable endometrial cancer (cancer of the womb). The main questions the study aims to answer are: * How well acasunlimab in combination with pembrolizumab works against endometrial cancer * What are the potential side effects participants may experience when they are treated with acasunlimab in combination with pembrolizumab Participants will receive both acasunlimab and pembrolizumab. All participants will receive active drug; no one will receive placebo. participants will participate in 1 of 2 cohorts. A participant will receive study treatment up to a maximum of 24 months. The study duration (including screening, treatment, and follow-up) for each participant will be about 39 months.

Conditions

  • Advanced Endometrial Cancer

Interventions

  • PembrolizumabBiological

    Pembrolizumab intravenous (IV) infusion

  • AcasunlimabBiological

    Acasunlimab IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Up to 4 years

Locations

29 sites in 6 countries. Site status is shown where the registry gives one.

  • Orlando Health Cancer Institute

    Orlando, Florida

  • Rudgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Grand Hospital de Charleroi

    Charleroi, Belgium

  • Universitair Ziekenhuis Ghent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Aalborg University Hospital

    Aalborg, Denmark

  • Rigshospitalet

    Copenhagen, Denmark

  • Odense Universitetshospital

    Odense, Denmark

  • AOU Policlinico Sant'Orsola Malpighi IRCCS

    Bologna, Italy

  • IRCCS Istituto Europeo di Oncologia IEO

    Milan, Italy

  • Fondazione G. Pascale

    Naples, Italy

  • IRCCS Policlinico Universitario Agostino Gemelli

    Roma, Italy

  • Ospedale Mauriziano Umberto I

    Torino, Italy

  • Keimyung University Dongsan Medical Center

    Daegu, South Korea

  • National Cancer Center Korea

    Goyang-si, South Korea

  • Pusan National University

    Pusan, South Korea

  • Seoul National University Bundang Hospital

    Seongnam, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System|Division of Infectious Diseases

    Seoul, South Korea

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • ICO Girona

    Girona, Spain

  • Clínica Universidad de Navarra

    Madrid, Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario Fundacion Jiménez Díaz

    Madrid, Spain

  • Clínica Universidad de Navarra

    Pamplona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.